Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Nanoscope Therapeutics will make two presentations at the 2022 ASRS meeting on their gene therapy programs to treat degenerative retinal diseases, retinitis pigmentosa and Stargardt disease.
Verve Therapeutics dosed its first patient with VERVE-101, a one-time treatment that aims to permanently lower low-density lipoprotein (LDL) cholesterol in patients and prevent heart disease.
Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.
Flagship Pioneering has launched Apriori Bio, which utilizes artificial intelligence to predict virus activity and variant formation, including COVID-19.
uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company’s president of R&D, Dr. Ricardo Dolmetsch.
Exelixis’ Cabometyx, in combination with two BMS-owned drugs, hit the primary endpoint of progression-free survival but missed the secondary endpoint of overall survival in renal cell carcinoma.
Roundworms are the cornerstone of scientific discoveries that have helped shape how we understand human disease and treatment. BioSpace takes a look at advances in C. elegans research.
Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).
Tonix Pharmaceuticals announced a mid-stage study for major depressive disorder, which followed the June disclosure of a Phase II study for a cocaine intoxication therapy.
Innoviva Inc. and La Jolla Pharmaceutical Company announced Monday that they had entered into a $149-million merger agreement.
The latest Employment Situation report from the Bureau of Labor Statistics shows that employment for healthcare workers is slowly but surely returning to its pre-pandemic levels.
The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.